Your cart is empty.
Männedorf, Switzerland, September 10, 2014 - Tecan Group (SIX Swiss Exchange: TECN) will hold its Capital Markets Day on Thursday, September 18, 2014 at its headquarter in Männedorf/Zurich, Switzerland. The event is open for analysts and institutional investors and will be hosted by CEO, Dr. David Martyr, along with other members of the management, who will give an update on Tecan's strategy as well as the 5 top level business priorities implemented for 2014. Presentations and product demos will also feature new product launches in the Life Sciences Business and Partnering Business divisions and provide additional insight into the recent acquisition of IBL International.
The presentation will begin at 08:30 a.m. CET and will be webcast live. The webcast may be accessed under the "Investor Relations" tab of Tecan's website www.tecan.com and is also available for mobile devices. All presentations will be in English.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2013, Tecan generated sales of CHF 388 million (USD 419 million; EUR 316 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89